SiBone (SIBN) versus Its Rivals Critical Contrast

SiBone (NASDAQ:SIBN) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its competitors? We will compare SiBone to similar companies based on the strength of its institutional ownership, earnings, dividends, risk, valuation, profitability and analyst recommendations.

Insider and Institutional Ownership

98.1% of SiBone shares are held by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 4.0% of SiBone shares are held by company insiders. Comparatively, 14.8% of shares of all “Healthcare Equipment & Supplies” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares SiBone and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
SiBone	$200.93 million	-$18.90 million	-78.19
SiBone Competitors	$1.89 billion	$137.77 million	9.47

SiBone’s competitors have higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of recent ratings for SiBone and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1	0	7	0	2.75
SiBone Competitors	4270	10539	18313	828	2.46

SiBone presently has a consensus price target of $25.00, suggesting a potential upside of 3.14%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 21.11%. Given SiBone’s competitors higher possible upside, analysts plainly believe SiBone has less favorable growth aspects than its competitors.

Profitability

This table compares SiBone and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SiBone	-6.20%	-7.57%	-5.55%
SiBone Competitors	-276.78%	-149.08%	-21.73%

Risk and Volatility

SiBone has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Comparatively, SiBone’s competitors have a beta of 2.70, meaning that their average stock price is 170% more volatile than the S&P 500.

Summary

SiBone competitors beat SiBone on 7 of the 13 factors compared.

About SiBone

SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.